For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Drugs made to treat diabetes and weight loss could stop or even reverse a severe liver disease, according to a new study. The ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.